Revance to Participate in Upcoming Investor Conferences
March 06 2018 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and underserved therapeutic conditions, today announced that the
company will participate in two upcoming investor conferences.
President and Chief Executive Officer, Dan Browne, is scheduled
to present at the Cowen and Company 38th Annual Health Care
Conference in Boston, MA on Tuesday, March 13 at 8:40am ET.
Chief Financial Officer and Chief Business Officer, Lauren
Silvernail, is scheduled to participate in a fireside chat
discussion at the Barclays Capital Healthcare Conference in Miami,
FL on Thursday, March 15 at 8:00am ET.
Interested parties can access the live audio webcasts for both
conferences from the Investor Relations section of the company's
website at www.revance.com. The webcast replays will be
available after the conclusion of the live presentations for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and
pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has
a comprehensive pipeline based upon its peptide technology,
including injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at
www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180306005219/en/
INVESTORSRevance Therapeutics, Inc.Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.Ami Bavishi,
212-213-0006abavishi@burnsmc.comorMEDIAGeneral Media:TOGORUNMariann
Caprino, 917-242-1087m.caprino@togorun.comorTrade Media:Nadine
Tosk, 504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024